As an SBIR awrdee ,Immunoshield Therapeutics Inc. is usually undersoood as developing cell therapies involving metabolic reprogramming of immune cells for treating and preventing diseases, including diabetes and kidney conditions, and for tissue regeneration. Company has received federal grant funding to support its research into islet transplantation and the genetic and functional analysis of diabetes-related kidney decline.
